AHA · Chicago · 2026-11-06 – 2026-11-09
AHA Scientific Sessions 2026
1 von 21 Studien (Late-Breaking Science) mit ErgebnisErgebnisse sind bis zur jeweiligen Präsentation gesperrt und erscheinen hier, sobald sie freigegeben sind.
Fr., 6. Nov.
Sa., 7. Nov.
LBS.01 The Dr. Eugene Braunwald Late-Breaking Science Session: Translating Science into Prevention: Lessons from Landmark Trials
08:35–09:50 (America/Chicago) · Center Stage, North Hall, Level 3- 08:35ZEUSKlinische StudiePrimary Report of the Ziltivekimab Cardiovascular Outcomes Trial (ZEUS)Präsentation Sa, 08:35
- 08:50Lp(a)HORIZON KernstudieKardiologie · Lipide · Lipoprotein(a)Bei 8.323 Patienten mit manifester kardiovaskulärer Erkrankung und Lp(a) ≥70 mg/dL senkte Pelacarsen 80 mg monatlich kardiovaskulären Tod, Myokardinfarkt, Schlaganfall oder dringliche Revaskularisation verglichen mit Placebo nicht.Lesen →
- 09:00Lp(a)HORIZON extended analysesBeobachtungsstudieExtended Analyses of Cardiovascular Outcomes With Pelacarsen Treatment in the Lp(a)Horizon TrialPräsentation Sa, 09:00
LBS.02 Late-breaking Science: Treating the Clot or Controlling the Blood Pressure: Improving Outcomes After Stroke
13:45–14:45 (America/Chicago) · Center Stage, North Hall, Level 3- 13:45OCEANIC-STROKE FraminghamBeobachtungsstudieOutcomes in the OCEANIC-STROKE Randomized, Placebo-Controlled Trial: FXIa Inhibition by Asundexian in Participants With Non-Cardioembolic Stroke or Transient Ischemic Attack by Non-Laboratory Framingham Risk Score CategoryPräsentation Sa, 13:45
- 14:00REDUCEKlinische StudieA Randomized Controlled Trial of Spironolactone-Based Blood Pressure Management After StrokePräsentation Sa, 14:00
- 14:15OPTIMAL-StrokeKlinische StudieIntensive Blood-Pressure Control for the Prevention of Major Cardiovascular Events in Patients With Prior Stroke: The OPTIMAL-Stroke TrialPräsentation Sa, 14:15
LBS.03 Late-breaking Science: Hot Topics in CVD Prevention
15:15–16:30 (America/Chicago) · Center Stage, North Hall, Level 3- 15:15STREAMKlinische StudieDiscontinuing Statins in Multimorbid Older Adults Without Cardiovascular Disease: A Randomized Non-Inferiority Clinical TrialPräsentation Sa, 15:15
- 15:30OPTIMAL-DIABETESKlinische StudieIntensive Blood Pressure Control for the Prevention of Major Cardiovascular Events in Patients With Type 2 Diabetes - The OPTIMAL-DIABETES TrialPräsentation Sa, 15:30
- 15:45Ez-PAVEKlinische StudieStatin-Ezetimibe Combination Therapy versus Statin Monotherapy in Patients With Atherosclerotic Cardiovascular Disease: Pre-Specified Second Randomization of the Ez-PAVE TrialPräsentation Sa, 15:45
- 16:00Yoga-CaRe HFKlinische StudieYoga-Based Cardiac Rehabilitation in Heart Failure With Reduced Ejection FractionPräsentation Sa, 16:00
So., 8. Nov.
LBS.04 Late-breaking Science: Innovations to Optimize Arrhythmia Care
15:30–16:45 (America/Chicago) · Center Stage, North Hall, Level 3- 15:30OptimPacingKlinische StudieLeft Bundle Branch Pacing versus Right Ventricular Pacing for Atrioventricular Block: An International Multi-Center Randomized Controlled Trial (OptimPacing Study)Präsentation So, 15:30
- 15:45COAST-AFKlinische StudieCharacterization of Arrhythmia Substrate to Ablate Persistent Atrial Fibrillation: COAST-AF Randomized TrialPräsentation So, 15:45
- 16:00SUPERIORKlinische StudieSacubitril/Valsartan for Preventing Recurrence of Atrial Fibrillation After Catheter Ablation in Patients With Hypertension: A Multicenter, Randomized Controlled TrialPräsentation So, 16:00
- 16:15RACE-CARSKlinische StudieRandomized Cluster Evaluation of Cardiac ARrest Systems (RACE-CARS) Trial Primary ResultsPräsentation So, 16:15
Mo., 9. Nov.
LBS.05 Late-breaking Science: New Frontiers in Cardiometabolic Risk Reduction
08:00–09:15 (America/Chicago) · Center Stage, North Hall, Level 3- 08:00TYDAL-TIMI 78Klinische StudieTYDAL-TIMI 78: A Randomized Trial of ANGPTL4 Inhibition With MAR001 in Adults With Elevated Triglycerides and Remnant Cholesterol ConcentrationsPräsentation Mo, 08:00
- 08:15CTX310Klinische StudieCRISPR-Cas9 Gene Editing Therapy Targeting ANGPTL3 for Severe Hypertriglyceridemia: Results From Phase 1b TrialPräsentation Mo, 08:15
- 08:30ATTAIN-OSAKlinische StudieOrforglipron for the Treatment of Obstructive Sleep Apnea: Results From Attain-OSAPräsentation Mo, 08:30
- 08:45SYNCHRONIZE-CVOTKlinische StudieSurvodutide and Cardiovascular Outcomes in Obesity: Results from the SYNCHRONIZE®-CVOT TrialPräsentation Mo, 08:45
LBS.06 Late-breaking Science: Artificial Intelligence in the Diagnosis of Cardiovascular Disease
09:45–11:00 (America/Chicago) · Center Stage, North Hall, Level 3- 09:55WATCH-LVBeobachtungsstudieConsumer Smartwatch Artificial Intelligence-Enabled Electrocardiogram for Left Ventricular Systolic Dysfunction: Cross-Manufacturer Validation and Serial Home MonitoringPräsentation Mo, 09:55
- 10:05PROVAR+BeobachtungsstudieAI-Enabled Tele-ECG Identifies Structural Heart Disease and Prioritizes Echocardiography in Underserved Populations: The PROVAR+ External Validation StudyPräsentation Mo, 10:05
- 10:22AI echo interpretation RCTKlinische StudieAI-Assisted Comprehensive Echocardiographic Interpretation—A Blinded, Randomized Controlled TrialPräsentation Mo, 10:22